Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART
24 March 2015. Related: Conference reports, Women's health, PK and drug interactions.
PK and drug interactions
Pharmacokinetics and safety of moxifloxacin in children
29 January 2015. Related: Conference reports, Paediatric care, PK and drug interactions.
Equivalent efficacy with lower dose darunavir
1 December 2014. Related: Antiretrovirals, PK and drug interactions.
Pharmacokinetic targets for efavirenz might be too high
24 March 2014. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Preventing and treating TB in children – more baby steps
1 December 2013. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Pharmacokinetics of etravirine with once-daily and twice-daily dosing
1 October 2013. Related: Antiretrovirals, PK and drug interactions.
Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above
29 May 2013. Related: Conference reports, Paediatric care, PK and drug interactions.
Bilirubin as a surrogate marker for atazanavir in children
29 May 2013. Related: Conference reports, Paediatric care, PK and drug interactions.
Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia
29 May 2013. Related: Conference reports, Pregnancy, PK and drug interactions.
Tenofovir population pharmacokinetics in pregnancy
29 May 2013. Related: Conference reports, Pregnancy, PK and drug interactions.
Effect of rifampicin on BMS-663068 in HIV negative volunteers
29 May 2013. Related: Conference reports, PK and drug interactions.
Coformulated darunavir/cobicistat: an alternative to separate ritonavir boosting
29 May 2013. Related: Conference reports, PK and drug interactions.
Continuous infusion of T-20 in multidrug resistant patient with intolerance of s.c. injections
29 May 2013. Related: Conference reports, PK and drug interactions.
Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Pharmacokinetics of currently available antiretroviral options for young children
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Safety of transplacental raltegravir in neonates and washout pharmacokinetics
1 April 2013. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Dietary requirements changed in Europe for fixed dose combination rilpivirine/tenofovir/FTC (Eviplera)
1 April 2013. Related: Antiretrovirals, PK and drug interactions.
Paediatric TB: glimpses of PK data and a potential new approach to drug development
1 February 2013. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Efavirenz interaction studies with TB compounds bedaquiline and delamanid
1 October 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Ritonavir significantly increases exposure to colchicine (gout)
1 October 2012. Related: PK and drug interactions.
Ritonavir interaction with quinine is clinically insignificant but may warrant caution
1 October 2012. Related: PK and drug interactions.
Case report: fluticasone, fluconazole and ritonavir interactions
1 October 2012. Related: PK and drug interactions.
Case reports of complications from ketamine use in two MSM on ritonavir-based combinations
1 June 2012. Related: Conference reports, PK and drug interactions.
Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations
1 June 2012. Related: Conference reports, PK and drug interactions, Side effects.
13th International workshop on Clinical Pharmacology of HIV Therapy, 16-18 April 2012, Barcelona
1 June 2012. Related: Conference reports, PK and drug interactions.
Studies on pipeline ARVs
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Washout pharmacokinetics of transplacental raltegravir in neonates
1 June 2012. Related: Conference reports, PK and drug interactions.
Interactions between malaria drugs and etravirine or darunavir/r
1 June 2012. Related: Conference reports, PK and drug interactions.
No interaction between antimalarial amodiaquine and nevirapine
1 June 2012. Related: Conference reports, PK and drug interactions.
Pharmacokinetics of atazanavir/ritonavir plus raltegravir
1 June 2012. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Atazanavir/ritonavir and voriconazole not to be coadministered
1 June 2012. Related: Conference reports, PK and drug interactions.
Milk thistle (silymarin) and darunavir/ritonavir
1 June 2012. Related: Conference reports, PK and drug interactions.
Echinacea and etravirine
1 June 2012. Related: Conference reports, PK and drug interactions.
Warfarin and ARVs: impact of African American race and ritonavir
1 June 2012. Related: Conference reports, PK and drug interactions.
Darunavir use during pregnancy
1 June 2012. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, PK and drug interactions.
FDA warning of drug interactions between boceprevir and some HIV protease inhibitors
1 April 2012. Related: PK and drug interactions.
Interactions between nevirapine and antimalarials (artemether and lumefantrine)
1 February 2012. Related: PK and drug interactions.
Interactions between antiretrovirals and complementary and African traditional medicines
1 February 2012. Related: PK and drug interactions.
Drug interactions between sirolimus (rapamycin) and ARVs
1 February 2012. Related: PK and drug interactions.
Contraceptive failure with etonogestrel implants and efavirenz: case reports
1 February 2012. Related: PK and drug interactions.
Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients
1 December 2011. Related: Conference reports, PK and drug interactions.
Ritonavir levels reduced with high fat meal
1 December 2011. Related: Conference reports, PK and drug interactions, Nutrition.
Monitoring kidney function change with cobicistat
1 December 2011. Related: Conference reports, PK and drug interactions.
Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily
1 December 2011. Related: Antiretrovirals, PK and drug interactions.
Switching to 50mg ritonavir dose for selected protease inhibitors
1 December 2011. Related: Antiretrovirals, PK and drug interactions.
Pharmacokinetics of darunavir and fosamprenavir in pregnancy
1 August 2011. Related: Conference reports, Pregnancy, PK and drug interactions.
Interactions between multivitamins or acid reducing agents and dolutegravir (S/GSK1349572)
1 August 2011. Related: PK and drug interactions.
Lopinavir and rifampicin interaction in HIV-positive patients
1 August 2011. Related: PK and drug interactions.
Case report: Cushings syndrome with atazanavir/ritonavir
1 August 2011. Related: PK and drug interactions.
Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART
1 August 2011. Related: Conference reports, PK and drug interactions, TB coinfection.
Quad reduces levels of oral contraceptives
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Elvitegravir/cobicistat and acid reducing agents
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Lopinavir/r reduces levels of rifabutin
1 May 2011. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Meeting report from 12th Pharmacology Workshop, Miami
1 May 2011. Related: PK and drug interactions.
Meeting report from 18th CROI, Boston
1 May 2011. Related: PK and drug interactions.
Atazanavir/ritonavir and combined oral contraceptives
1 May 2011. Related: PK and drug interactions.
No interaction between raltegravir and oral contraceptives
1 April 2011. Related: PK and drug interactions.
Case report: extreme bradycardia with lopinavir/ritonavir and metoprolol and lacidipine
1 April 2011. Related: PK and drug interactions.
Complex connections between bone and fat metabolism
1 February 2011. Related: Conference reports, PK and drug interactions, Lipodystrophy and metabolic complications.
Raltegravir and unboosted atazanavir
1 February 2011. Related: PK and drug interactions.
Etravirine interactions
1 February 2011. Related: PK and drug interactions.
ARVs and targeted cancer therapies
1 February 2011. Related: PK and drug interactions.
Pharmacokinetics of lopinavir/ritonavir incombination with rifampicin based TB treatment in children
1 December 2010. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Higher risk of potential drug-drug interactions in HIV patients over 60
1 December 2010. Related: Conference reports, PK and drug interactions.
Smoking and atazanavir levels
26 August 2010. Related: Conference reports, PK and drug interactions.